CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Impairment loss	$ 34,169	$ 0
Net loss	(8,213,094)	(8,030,074)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	233,909	248,958
Stock-based compensation expense	459,085	348,901
Change in fair value of derivative financial instruments—warrants	42,037	(14,028)
Release of clinical trial funding commitment	506,509	310,766
Changes in operating assets and liabilities:
Other assets	4,991	(32,464)
Accounts receivable and unbilled receivable	94,146	45,474
Prepaid expenses	(29)	163,950
Operating lease right-of-use assets	161,355	147,974
Accounts payable and accrued expenses	(514,239)	387,046
Operating lease liabilities	(418,959)	(379,662)
Other liabilities	(55,667)	0
Net cash used in operating activities	(7,665,787)	(6,803,159)
Investing activities:
Capital expenditures	0	(5,274)
Net cash used in investing activities	0	(5,274)
Financing activities:
Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $92,648 and $97,260, respectively	18,801,924	2,902,740
Costs related to the clinical trial funding commitment	(7,500)	(40,000)
Proceeds from exercise of warrants, net of expenses of $393,285 and $0, respectively	6,125,884	3,283,830
Borrowings under long-term debt	305,000	0
Net cash provided by financing activities	25,225,308	6,146,570
Net change in cash and cash equivalents	17,559,521	(661,863)
Cash and cash equivalents—Beginning of period	10,195,292	11,453,133
Cash and cash equivalents—End of period	27,754,813	10,791,270
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	800
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of property and equipment included in accounts payable and accrued expenses	11,453	0
Expenses from sales of common stock, preferred stock and warrants included in accounts payable and accrued liabilities	523,495	0
Expenses from exercise of warrants included in accounts payable and accrued liabilities	64,498	0
Preferred stock dividend payable on Series A Convertible Preferred Stock	12,120	12,120
Series C Convertible Preferred Stock
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance	0	268,269
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment	0	1,675,000
Common stock issued upon conversion of convertible preferred stock	0	33
Series D Convertible Preferred Stock
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance	601,767	0
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment	2,300,000	0
Common stock issued upon conversion of convertible preferred stock	155	0
Series E Convertible Preferred Stock
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance	$ 2,664,717	$ 0